NEWS
Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences
Codexis, Inc. (NASDAQ: CDXS) has entered into a non-exclusive commercial and manufacturing license agreement with Alphazyme , part of Maravai LifeSciences, for multiple enzymes in Codexis' life science enzyme portfolio. The agreement includes licenses for HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostics applications.
Codexis will receive sales-based royalties under the agreement. This transaction aligns with Codexis' strategy to divest non-core assets following its strategic shift announced in July 2023. The company aims to focus on maximizing near-term commercial opportunities, including growing its Pharmaceutical Manufacturing business, increasing adoption of dsRNA ligase, and developing the ECO Synthesis™ Innovation Lab.
Codexis expects to achieve key milestones for the ECO Synthesis™ platform this fiscal year, deliver double-digit product revenue growth, and maintain a path to positive cash flow around the end of 2026.
Codexis will receive sales-based royalties under the agreement. This transaction aligns with Codexis' strategy to divest non-core assets following its strategic shift announced in July 2023. The company aims to focus on maximizing near-term commercial opportunities, including growing its Pharmaceutical Manufacturing business, increasing adoption of dsRNA ligase, and developing the ECO Synthesis™ Innovation Lab.
Codexis expects to achieve key milestones for the ECO Synthesis™ platform this fiscal year, deliver double-digit product revenue growth, and maintain a path to positive cash flow around the end of 2026.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2879Followers
108Following
30KVisitors
Follow